Trial reportAnnals of surgical oncology2024
Results of a Prospective Randomized Multicenter Study Comparing Indocyanine Green (ICG) Fluorescence Combined with a Standard Tracer Versus ICG Alone for Sentinel Lymph Node Biopsy in Early Breast Cancer: The INFLUENCE Trial.
Trial report in Annals of surgical oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Use of indocyanine green fluorescence versus patent blue V dye for sentinel lymph node biopsy in early breast cancer, a randomized controlled trial.Journal of the Egyptian National Cancer Institute · 2026Trial
- Navigating lymphatic drainage uncertainty in abdominal ectopic breast cancer: a novel application of indocyanine green fluorescence-a case report and literature review.International cancer conference journal · 2026Article
- ASO Author Reflections: From Feasibility to Implementation: Establishing Indocyanine Green as a Single-Tracer Strategy for Sentinel Lymph Node Biopsy in Breast Cancer.Annals of surgical oncology · 2026Article
- ICG-only Sentinel Lymph Node Biopsy in Breast Cancer: A Prospective UK Cohort Demonstrating Consistent Detection Across Patient and Tumour Characteristics-A Follow-on to the INFLUENCE Trial.Annals of surgical oncology · 2026Article
- Comparison of Indocyanine Green Versus Isosulfan Blue in Melanoma Sentinel Node Biopsy.Annals of surgical oncology · 2026Article
- Indocyanine Green as a Single Tracer for Axillary Staging in Breast Cancer: A Retrospective Single-Centre Cohort Study.Cancers · 2026Article
- Article
- Article
- Establishing a standardized robotic approach for technetium-99 m-defined sentinel lymph node dissection with indocyanine green-guided navigation in da Vinci Xi & SP system.Journal of robotic surgery · 2026Article
- Clinicopathological factors associated with sentinel lymph node positivity in breast cancer using indocyanine green: a retrospective study in Peru.World journal of surgical oncology · 2026Article
- Comparative analysis of indocyanine green and technetium-99m for sentinel lymph node localization in breast cancer - institutional experience.Frontiers in oncology · 2026Article
- Fluorescence-Guided Surgery in Pediatric Oncology: Current Practice and Future Directions.Cancers · 2025Review
- Triple-Tracer Sentinel Node Mapping: Maximizing Detection, Minimizing Dissection.Life (Basel, Switzerland) · 2025Article
- From Gamma Rays to Green Light: Comparative Efficacy of Indocyanine Green and Technetium-99m in Sentinel Lymph Node Biopsy for Breast Cancer.Medical sciences (Basel, Switzerland) · 2025Observational
- Dual-wavelength photoacoustic imaging of sentinel lymph nodes in patients with melanoma and breast cancer.Photoacoustics · 2025Article
- Indocyanine green versus technetium-99m for sentinel lymph node biopsy in breast cancer: the FLUORO trial.BJS open · 2025Article
- A Dose-Image Optimization Trial for Voluven®-Assisted Indocyanine Green Fluorescence-Guided Breast Cancer Sentinel Lymph Node Surgery.Annals of surgical oncology · 2025Article
- The use of indocyanine green and technetium-99 for dual-tracer sentinel lymph node biopsy in breast cancer.Breast cancer research and treatment · 2025Article
- Letter to the Editor in Relation to "Results of a Prospective Randomized Multicenter Study Comparing Indocyanine Green (ICG) Fluorescence Combined with a Standard Tracer Versus ICG Alone for Sentinel Lymph Node Biopsy in Early Breast Cancer: The INFLUENCE Trial".Annals of surgical oncology · 2025Article
- ASO Author Reflections: ICG Fluorescent-Guided Surgery for Sentinel Lymph Node Biopsy Used as a Single Tracer Shown Sensitivity, Safety, and Efficacy in Early Breast Cancer Surgery.Annals of surgical oncology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFor clinically node-negative early breast cancer patients, sentinel lymph node biopsy (SLNB) using dual localization with blue dye and radioisotope (RI) is currently standard of care. Documented disadvantages with these tracers have prompted exploration of alternative agents such as fluorescent indocyanine green (ICG), which demonstrates high detection rates combined with other tracers. Results of a randomized study evaluating ICG as a single tracer for SLN identification are presented.
methodsOverall, 100 patients with unilateral, clinically node-negative, biopsy-proven invasive breast cancer (≤5 cm) scheduled for SLNB were recruited in two separate randomized cohorts, with 50 patients receiving ICG alone. Cohort 1 received ICG alone (n = 25) or combined with RI [Technetium
resultsAmong evaluable patients (n = 97), the overall SLN identification rate was 96.9% (ICG alone = 97.9%; ICG + RI = 100%; ICG + blue dye = 92%). Node positivity rates were 14.9% for ICG alone, 16% for ICG combined with RI, and 20% for ICG combined with blue dye. There were no significant differences (p < 0.05) in performance parameters, with ICG alone being non-inferior to tracer combinations for procedural node positivity rates when adjusted for specific factors.
conclusionThese results support potential use of ICG as a sole tracer agent for routine SLNB, thereby avoiding disadvantages of RI and/or blue dye. The latter can be safely withheld as a co-tracer without compromising detection of positive nodes in primary surgical patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.